Focus: BioCryst is a specialty pharmaceutical company focused on small-molecule therapies, primarily concentrated in rare disease and neurology. The company is public (NASDAQ: BCRX) and headquartered in Durham, NC, with a single commercial product generating all revenue.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Growing — net +5 jobs in 30d
13 jobs added vs 8 removed. Steady team buildout.
Recent layoff filing — 47 affected
Source: state DOL filings via Big Local News
BioCryst is a focused rare-disease player with strong commercial momentum in a single asset, but revenue concentration and recent restructuring signal near-term instability despite a credible pipeline.
Help build intelligence for BioCryst Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BioCryst Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole commercial revenue driver; plasma kallikrein inhibitor approved for C1-INH deficiency or dysfunction in HAE, with patent protection until 2040.
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas Stocktwits
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook RTTNews
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - The Manila Times
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio The Manila Times
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - Yahoo Finance
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio Yahoo Finance
BioCryst is profitable. Now it wants to buy more rare disease drugs - CNBC
BioCryst is profitable. Now it wants to buy more rare disease drugs CNBC
BioCryst Pharma wins Japanese approval of Orladeyo in pediatric HAE patients - The Pharma Letter
BioCryst Pharma wins Japanese approval of Orladeyo in pediatric HAE patients The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: state DOL filings, aggregated via Big Local News
Recent restructuring, rapid cash burn ($194M decline YoY), and hiring freeze create near-term employment instability despite revenue growth.
Recent peer-reviewed publications with author affiliations at this company
Optimizing conversations on treatment management in hereditary angioedema: healthcare professional and patient perspectives on long-term prophylaxis and shared decision-making.
Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo